# Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

> **NCT03512262** · PHASE3 · COMPLETED · sponsor: **Radius Health, Inc.** · enrollment: 228 (actual)

## Conditions studied

- Osteoporosis
- Osteoporosis, Age-Related
- Osteoporosis Localized to Spine
- Age Related Osteoporosis
- Osteoporosis Senile
- Osteoporosis of Vertebrae

## Interventions

- **DRUG:** Abaloparatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03512262
- **Lead sponsor:** Radius Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-03
- **Primary completion:** 2021-08-17
- **Final completion:** 2021-09-08
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03512262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03512262, "Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03512262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*